(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). While the risk of disease progression is non-negligible, a significant portion of the health care burden associated with this condition is due to recurrence. Previous studies have demonstrated that the use of blue light flexible cystoscopy (BLFC) may increase the detection of additional cancers missed with white light cystoscopy (WLC) alone. However, its role in the surveillance of patients following intravesical therapy has not been established. In a podium presentation at the American Urologic Association Virtual Annual Meeting, Dr. Seyedian and colleagues presented the results of their analysis examining this question.